Projects per year
Abstract
Objectives: Hypermutable bacteria are causing a drastic problem via their enhanced ability to become resistant. Our objectives were to compare bacterial killing and resistance emergence between differently shaped tobramycin concentration-time profiles at a given fAUC/MIC, and determine the tobramycin exposure durations that prevent resistance. Methods: Static concentration time-kill studies over 24 h used Pseudomonas aeruginosa WT strains (ATCC 27853 and PAO1) and hypermutable PAOΔmutS. fAUC/MIC values of 36, 72 and 168 were assessed at initial inocula of 106 and 104 cfu/mL (all strains) and 101.2 cfu/mL (PAOΔmutS only) in duplicate. Tobramycin was added at 0 h and removed at 1, 4, 10 or 24 h. Proportions of resistant bacteria and MICs were determined at 24 h. Mechanism-based modelling was conducted. Results: For all strains, high tobramycin concentrations over 1 and 4 h resulted in more rapid and extensive initial killing compared with 10 and 24 h exposures at a given fAUC/MIC. No resistance emerged for 1 and 4 h durations of exposure, although extensive regrowth of susceptible bacteria occurred. The 24 h duration of exposure revealed less regrowth, but tobramycin-resistant populations had completely replaced susceptible bacteria by 24 h for the 106 cfu/mL inoculum. The hypermutable PAOΔmutS showed the highest numbers of resistant bacteria. Total and resistant bacterial counts were described well by novel mechanism-based modelling. Conclusions: Extensive resistance emerged for 10 and 24 h durations of exposure, but not for shorter durations. The tobramycin concentration-time profile shape is vital for resistance prevention and should aid the introduction of optimized combination regimens.
Original language | English |
---|---|
Pages (from-to) | 3157-3167 |
Number of pages | 11 |
Journal | Journal of Antimicrobial Chemotherapy |
Volume | 71 |
Issue number | 11 |
DOIs | |
Publication status | Published - 1 Nov 2016 |
Projects
- 4 Finished
-
Targeting hypermutable 'superbugs' in chronic respiratory infections by optimised antibiotic combination dosage regimens
Landersdorfer, C. (Primary Chief Investigator (PCI)), Boyce, J. (Chief Investigator (CI)), Bulitta, J. (Chief Investigator (CI)), Nation, R. (Chief Investigator (CI)) & Oliver, A. (Chief Investigator (CI))
National Health and Medical Research Council (NHMRC) (Australia)
1/01/16 → 31/12/19
Project: Research
-
Targeting bacterial 'superbugs' by innovative combination dosing strategies and new antibiotics
Bulitta, J.
National Health and Medical Research Council (NHMRC) (Australia)
1/03/15 → 28/02/19
Project: Research
-
Combating bacterial 'superbugs' by innovative antibiotic combination strategies
Landersdorfer, C. (Primary Chief Investigator (PCI))
National Health and Medical Research Council (NHMRC) (Australia)
1/01/14 → 31/12/17
Project: Research